Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BC106 insulin lispro · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Insulin Lispro | ACTIVE_COMPARATOR | 15 international units (IU) insulin lispro administered once subcutaneously (SC) during 1 of 3 dosing periods. There is a minimum 7 day washout between dosing periods. |
| BC106 Insulin Lispro | EXPERIMENTAL | 15 up to 30 IU BC106 insulin lispro administered once SC during 2 of 3 dosing periods. There is a minimum 7 day washout between dosing periods. |
| Name | Type | Description |
|---|---|---|
| Insulin Lispro | DRUG | Administered SC |
| BC106 insulin lispro | DRUG | Administered SC |
Inclusion Criteria: * Are not of child-bearing potential * Have a body mass index (BMI) between 18 and 29.9 kilograms per square meter (kg/m\^2), inclusive * Are nonsmokers or have not smoked for at least 6 months prior to entering the study * Have a fasting plasma glucose less than 6.0 millimoles ...
BC106 insulin lispro is an investigational small molecule being studied in healthy participants. It is a formulation of insulin lispro combined with a BioChaperone excipient, intended for evaluation in a Phase 1 clinical trial. The study focuses on healthy volunteers to assess the product's effects.
BC106 insulin lispro is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The company is conducting a Phase 1 clinical trial to evaluate this insulin lispro formulation with a BioChaperone excipient in healthy participants.
BC106 insulin lispro is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 study has been completed, with results not yet publicly reported.
BC106 insulin lispro has one completed clinical trial, NCT01638325, titled "A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants." This Phase 1 study enrolled 37 participants in Singapore, was randomized and active-controlled, and included healthy volunteers aged 21 years and older.
BC106 insulin lispro is a specific formulation of insulin lispro that includes a BioChaperone excipient. While it contains insulin lispro, the addition of the BioChaperone excipient distinguishes it as a separate investigational product being studied for its unique properties.